Clinical Edge Journal Scan Commentary: HCC January 2022

Several novel options for the treatment of unresectable hepatocellular carcinoma (uHCC) have been evaluated over the past few years. This month, we will review recently published articles that address systemic therapies for uHCC. For many years, sorafenib was the only FDA-approved systemic treatment for patients with uHCC. Initial case reports of remarkable responses…

Read the full article here

Related Articles